Answers are grounded in this paper and cite their sources.
Analyzes relationship between sFlt-1/PlGF ratio and preterm birth risk, suggesting its utility in pregnancy management.
AIM: To analyze the relationship between the fibroblast growth factor soluble receptor 1 (sFlt-1/PlGF) ratio and adverse perinatal outcomes. MATERIALS AND METHODS: Patients admitted between 22+0 and 34+6 weeks of gestation from February 2024 to June 2025 were included. The sFlt-1/PlGF ratio was measured and its relationship to pregnancy outcome was evaluated. We assessed whether patients with increased sFlt-1/PlGF ratios developed conditions leading to preterm birth (spontaneous or iatrogenic). RESULTS: A total of 78 patients were included, of whom 47 delivered before 37 weeks of gestation and 31 after 37 weeks. The sFlt-1/PlGF ratio appeared significant in relation to the risk of preterm birth. Almost all women with an sFlt-1/PlGF ratio above 100 delivered before 37 weeks. Based on the collected data, we developed a model to estimate the probability of delivery within 3 or 7 days. The model showed low sensitivity (0.32 and 0.53), but high specificity (0.91 in both cases). It accurately identified patients who would not deliver within 3 or 7 days. CONCLUSION: The sFlt-1/PlGF ratio is a useful tool in assessing the further course of pregnancy.
No takes yet. Share an insight, caveat, or question.
Piklová et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: